Comparative Pharmacology
Head-to-head clinical analysis: CONSENSI versus HARMONYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSENSI versus HARMONYL.
CONSENSI vs HARMONYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Consensi is a fixed-dose combination of amlodipine, a dihydropyridine calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Celecoxib inhibits prostaglandin synthesis via COX-2, reducing inflammation and pain.
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Adults: 0.25 mg/kg intravenously over 1 hour every 2 weeks.
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
None Documented
None Documented
Terminal elimination half-life of 12-15 hours for parent drug and 18-24 hours for active metabolite, allowing once-daily dosing.
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
Primarily renal (70-80% as unchanged drug and active metabolite desmethyl-consensi); biliary/fecal: 15-20%.
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antihypertensive/NSAID Combination
Antihypertensive